Incretin mimetic anti-obesity medications
1 paper3 findings
- 1 lab
- Humans1
Outcomes
3Blood glucose
downin humans1
1 study
Blood glucose
downin humans1
Incretin mimetic anti-obesity medications decrease blood glucose in humans (-5.40 mg/dL).
“The respective 6-month changes in SBP and BGL during AOM use were -5.80 mmHg and -5.40 mg/dL.”
Humans6 months
Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use
ADA Scientific Sessions 2026 abstract5 Jun 2026
Systolic blood pressure
downin humans1
1 study
Systolic blood pressure
downin humans1
Incretin mimetic anti-obesity medications decrease systolic blood pressure in humans (-5.80 mmHg).
“The respective 6-month changes in SBP and BGL during AOM use were -5.80 mmHg and -5.40 mg/dL.”
Humans6 months
Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use
ADA Scientific Sessions 2026 abstract5 Jun 2026
Body mass index
downin humans1
1 study
Body mass index
downin humans1
Incretin mimetic anti-obesity medications decrease body mass index in humans (from 36.74 kg/m2 at baseline to 34.55 kg/m2 at month 6).
“The unadjusted mean BMI decreased from 36.74 kg/m2 at baseline to 34.55 kg/m2 at month 6 on AOM.”
Humans6 months
Cardiometabolic Risk Trajectories On and After Antiobesity Medication Use
ADA Scientific Sessions 2026 abstract5 Jun 2026